P2.04-17 Pre-Therapy Radiomic Features Can Distinguish Hyperprogression From Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC

Journal of Thoracic Oncology- United States

doi 10.1016/j.jtho.2018.08.1241

Full Text

Abstract

Available in

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Automated Image Analysis of NSCLC Biopsies to Predict Response to Anti-Pd-L1 Therapy

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Value in Health

Occupational Health

English

Understanding the Role of PD-L1/PD1 Pathway Blockade and Autophagy in Cancer Therapy

OncoTargets and Therapy

English

Continuous Targeted Kinase Inhibitors Treatment Induces Upregulation of PD-L1 in Resistant NSCLC

Scientific Reports

Multidisciplinary

English

P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population

Journal of Thoracic Oncology

Respiratory Medicine

English

Ability of 18f-FDG PET/CT Radiomic Features to Distinguish Breast Carcinoma From Breast Lymphoma

Contrast Media and Molecular Imaging

Nuclear Medicine

English

MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples

Journal of Thoracic Oncology

Respiratory Medicine

English

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study Using Targeted Therapy in NSCLC

Scientific Reports

Multidisciplinary

English